Global Radioligand Therapy 麻豆原创 Research Report 2023

Publication ID:

PB502239996

Publication Date:

February 20, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Radioligand Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Radioligand Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Radioligand Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Radioligand Therapy in Neuroendocrine Neoplasms is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Radioligand Therapy include Novartis, Advanced Accelerator Applications, Mercy Radiology, POINT Biopharma Global Inc, Fusion Pharma, Telix Pharmaceuticals Ltd, Lantheus Holdings, Inc, Bayer AG and Curium Pharma, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Radioligand Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioligand Therapy.
The Radioligand Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Radioligand Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radioligand Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novartis
Advanced Accelerator Applications
Mercy Radiology
POINT Biopharma Global Inc
Fusion Pharma
Telix Pharmaceuticals Ltd
Lantheus Holdings, Inc
Bayer AG
Curium Pharma
Precirix
Segment by Type
Actinium 225 (Ac-225)
Lutetium 177 (Lu-177)
Gallium 68 (Ga-68)
Fluorine 18 (F-18)
Other Radionuclides
Segment by Application
Neuroendocrine Neoplasms
Prostate Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radioligand Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Radioligand Therapy 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Actinium 225 (Ac-225)
1.2.3 Lutetium 177 (Lu-177)
1.2.4 Gallium 68 (Ga-68)
1.2.5 Fluorine 18 (F-18)
1.2.6 Other Radionuclides
1.3 麻豆原创 by Application
1.3.1 Global Radioligand Therapy 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Neuroendocrine Neoplasms
1.3.3 Prostate Cancer
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radioligand Therapy 麻豆原创 Perspective (2018-2029)
2.2 Radioligand Therapy Growth Trends by Region
2.2.1 Global Radioligand Therapy 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Radioligand Therapy Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Radioligand Therapy Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Radioligand Therapy 麻豆原创 Dynamics
2.3.1 Radioligand Therapy Industry Trends
2.3.2 Radioligand Therapy 麻豆原创 Drivers
2.3.3 Radioligand Therapy 麻豆原创 Challenges
2.3.4 Radioligand Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radioligand Therapy Players by Revenue
3.1.1 Global Top Radioligand Therapy Players by Revenue (2018-2023)
3.1.2 Global Radioligand Therapy Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Radioligand Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radioligand Therapy Revenue
3.4 Global Radioligand Therapy 麻豆原创 Concentration Ratio
3.4.1 Global Radioligand Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioligand Therapy Revenue in 2022
3.5 Radioligand Therapy Key Players Head office and Area Served
3.6 Key Players Radioligand Therapy Product Solution and Service
3.7 Date of Enter into Radioligand Therapy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioligand Therapy Breakdown Data by Type
4.1 Global Radioligand Therapy Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Radioligand Therapy Forecasted 麻豆原创 Size by Type (2024-2029)
5 Radioligand Therapy Breakdown Data by Application
5.1 Global Radioligand Therapy Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Radioligand Therapy Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Radioligand Therapy 麻豆原创 Size (2018-2029)
6.2 North America Radioligand Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Radioligand Therapy 麻豆原创 Size by Country (2018-2023)
6.4 North America Radioligand Therapy 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radioligand Therapy 麻豆原创 Size (2018-2029)
7.2 Europe Radioligand Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Radioligand Therapy 麻豆原创 Size by Country (2018-2023)
7.4 Europe Radioligand Therapy 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radioligand Therapy 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Radioligand Therapy 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Radioligand Therapy 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Radioligand Therapy 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radioligand Therapy 麻豆原创 Size (2018-2029)
9.2 Latin America Radioligand Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Radioligand Therapy 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Radioligand Therapy 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radioligand Therapy 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Radioligand Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Radioligand Therapy 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Radioligand Therapy 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Radioligand Therapy Introduction
11.1.4 Novartis Revenue in Radioligand Therapy Business (2018-2023)
11.1.5 Novartis Recent Development
11.2 Advanced Accelerator Applications
11.2.1 Advanced Accelerator Applications Company Detail
11.2.2 Advanced Accelerator Applications Business Overview
11.2.3 Advanced Accelerator Applications Radioligand Therapy Introduction
11.2.4 Advanced Accelerator Applications Revenue in Radioligand Therapy Business (2018-2023)
11.2.5 Advanced Accelerator Applications Recent Development
11.3 Mercy Radiology
11.3.1 Mercy Radiology Company Detail
11.3.2 Mercy Radiology Business Overview
11.3.3 Mercy Radiology Radioligand Therapy Introduction
11.3.4 Mercy Radiology Revenue in Radioligand Therapy Business (2018-2023)
11.3.5 Mercy Radiology Recent Development
11.4 POINT Biopharma Global Inc
11.4.1 POINT Biopharma Global Inc Company Detail
11.4.2 POINT Biopharma Global Inc Business Overview
11.4.3 POINT Biopharma Global Inc Radioligand Therapy Introduction
11.4.4 POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (2018-2023)
11.4.5 POINT Biopharma Global Inc Recent Development
11.5 Fusion Pharma
11.5.1 Fusion Pharma Company Detail
11.5.2 Fusion Pharma Business Overview
11.5.3 Fusion Pharma Radioligand Therapy Introduction
11.5.4 Fusion Pharma Revenue in Radioligand Therapy Business (2018-2023)
11.5.5 Fusion Pharma Recent Development
11.6 Telix Pharmaceuticals Ltd
11.6.1 Telix Pharmaceuticals Ltd Company Detail
11.6.2 Telix Pharmaceuticals Ltd Business Overview
11.6.3 Telix Pharmaceuticals Ltd Radioligand Therapy Introduction
11.6.4 Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (2018-2023)
11.6.5 Telix Pharmaceuticals Ltd Recent Development
11.7 Lantheus Holdings, Inc
11.7.1 Lantheus Holdings, Inc Company Detail
11.7.2 Lantheus Holdings, Inc Business Overview
11.7.3 Lantheus Holdings, Inc Radioligand Therapy Introduction
11.7.4 Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (2018-2023)
11.7.5 Lantheus Holdings, Inc Recent Development
11.8 Bayer AG
11.8.1 Bayer AG Company Detail
11.8.2 Bayer AG Business Overview
11.8.3 Bayer AG Radioligand Therapy Introduction
11.8.4 Bayer AG Revenue in Radioligand Therapy Business (2018-2023)
11.8.5 Bayer AG Recent Development
11.9 Curium Pharma
11.9.1 Curium Pharma Company Detail
11.9.2 Curium Pharma Business Overview
11.9.3 Curium Pharma Radioligand Therapy Introduction
11.9.4 Curium Pharma Revenue in Radioligand Therapy Business (2018-2023)
11.9.5 Curium Pharma Recent Development
11.10 Precirix
11.10.1 Precirix Company Detail
11.10.2 Precirix Business Overview
11.10.3 Precirix Radioligand Therapy Introduction
11.10.4 Precirix Revenue in Radioligand Therapy Business (2018-2023)
11.10.5 Precirix Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Novartis
Advanced Accelerator Applications
Mercy Radiology
POINT Biopharma Global Inc
Fusion Pharma
Telix Pharmaceuticals Ltd
Lantheus Holdings, Inc
Bayer AG
Curium Pharma
Precirix

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.